
Medtronic retired. ham. cycle. XC ski. invent. fundraise for diabetes. founded WAMXC(https://xitter.cf/t.co/UNlTrSIUym) in 2000. @tobymarkowitz@mas.to
Minnesota, USA
Joined January 2009
- Tweets14.4K
- Following93
- Followers263
- Likes20.7K
Toby Markowitz retweeted
In a sea of irrational exuberance and widespread uncritical appraisal, stands Louisiana Blue Cross insurers, who, wisely IMO, changed LAAC status to experimental after CLOSURE and CHAMPION
Dr. Sanket Dhruva explains jacc.org/doi/10.1016/j.jacc.…
Toby Markowitz retweeted
Atrial fibrillation begets atrial fibrillation revisited: Early entrenchment of AF episodes #OpenAccess
heartrhythmjournal.com/artic…
Toby Markowitz retweeted
Thirty-two-inch bikes have had their moment in the spotlight, but skeptics remain. Stephen Fitzgerald of Rodeo Labs was one of them, until curiosity got the better of him. Read the story of Project 32:bikepacking.com/plog/project…
Toby Markowitz retweeted
For nearly 20 years, our teams have worked to understand #AFib through the biology of the #atrial substrate. What began as a hypothesis around atrial fibrosis is becoming increasingly clear.
The question may no longer be simply: PVI versus substrate ablation?
The more important question is: Which AF patient has a modifiable atrial substrate, where is it, and can we reliably eliminate it?
DECAAF I established that atrial fibrosis matters and strongly predicts ablation outcome.
DECAAF II then tested MRI-guided fibrosis ablation in persistent AF. The overall trial was neutral, but the mechanistic lesson was important: identifying fibrosis alone was not enough. Intended ablation did not always translate into durable scar, and benefit appeared related to both disease extent and effective substrate coverage.
IDEAL-AF and COAST-AF now add another piece.
IDEAL-AF selected only patients with meaningful low-voltage substrate for randomization. When that substrate was specifically targeted with clear electrical endpoints, outcomes improved substantially over PVI alone.
COAST-AF tells a similar story. The overall trial was negative, but among patients who actually had low-voltage areas, substrate ablation significantly improved outcomes. Patients without demonstrable substrate did not appear to benefit.
These studies may therefore be defining the same biology from different directions:
No significant atrial substrate → PVI may be enough.
A demonstrable, modifiable atrial myopathy → PVI alone may be inadequate.
Advanced, diffuse disease → simply adding more ablation may not overcome the biology.
The next phase of AF ablation should move beyond “more ablation” toward precision substrate therapy: identify the AF fibrosis/myopathy phenotype, select the right patient, define the abnormal tissue accurately, and ensure that it is truly modified or isolated.
The future is not empiric substrate ablation. It is targeting the AF substrate in the right patient, at the right stage of disease.
@chris_sohns @PrashSanders @peterkistler3 @S_NarayanMD @Phiso_de @netta_doc @TinaBaykaner @DrRoderickTung @Ed_Gerst @shivkumarmd @Siddmann @gautamsand @drjohnm @TulaneTriad
Presented at #ScientificSessions26: In a prespecified principal subgroup of patients with low-voltage areas, adjunctive low-voltage area ablation with pulmonary vein isolation was associated with lower atrial arrhythmia recurrence and lower atrial fibrillation burden than pulmonary vein isolation alone.
These findings indicate that substrate-guided ablation may have relevance for treatment selection in patients with persistent #AtrialFibrillation who have low-voltage areas identified during mapping.
ja.ma/4iFimDE
Toby Markowitz retweeted
Pretty important 👇🏻
Paper out in @escardio #EHJ, lead by #milanmilojevic: time-dependent late mortality in a pooled analysis of trials
TL:DR: the hazard for all-cause mortality changes at 1.9 years, with 5-7 years HR of 1.64 (p < 0.001) in favor of #SAVR
@EACTS @ctsnetorg
academic.oup.com/eurheartj/a…
Toby Markowitz retweeted
Credit to the EP team in Bern for this excellent remapping study after either RF or PFA. Mandated remapping is much better than remapping for symptoms jacc.org/doi/10.1016/j.jacep…
A) PFA no better than RF for durable PVI
B) Recapitulates GAP study showing that AF still occurs in one-third of durably isolated PVs and 72% of those with reconnected veins DID NOT have AF at one year
This is the crux of our problem in EP: we don't understand the pathophysiology of the condition. PVs get isolated because we can. @TobiasReichlin
Toby Markowitz retweeted
Very fitting to have a joint Physiologic Pacing session @APHRSOfficial with @NatRevCardiol in Busan, with #PPS10 in two short weeks.
Our review led by Drs. Lee & Choi @Hisdoc1 @Dr_JozaEP @lusty63 @Marek_Jastrz_EP @MdHuang @HaranBurri @shunmug_his_mdu now online in Nature!
nature.com/articles/s41569-0…
Toby Markowitz retweeted
Remarkable finding
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial academic.oup.com/eurheartj/a… #digoxin #heartfailure via @ESC_Journals
Toby Markowitz retweeted
Non-invasive assessment of left atrial activation using lead V8 during Bachmann bundle pacing
academic.oup.com/europace/ar…
@Dominik_Linz @Dr_JozaEP @lusty63 @Hisdoc1 @Marek_Jastrz_EP
Toby Markowitz retweeted
Very important message from our group. In patients with recurrent AF after a first ablation, what we do next matters. Repeat catheter ablation was associated with a 35% lower risk of death, stroke, or HF hospitalization compared with cardioversion, with an NNT of only 14.
This challenges the idea that management of recurrent AF should simply be based on operator preference. Recurrence after ablation should not be viewed as failure—it may be an opportunity to intervene again and improve meaningful clinical outcomes.
Congratulations to @mabou_khalil @HanFengGHD @QMarashly and the entire team. #AFib #Ablation #EPeeps
@PrashSanders @shivkumarmd @gautamsand @S_NarayanMD @Phiso_de @drsuneet @drjohnm @drluissaenz @leftbundle @KennethEllenbo1 @DrBradleyKnight @DrRoderickTung @atulverma_md
AF recurs in up to 50% post-ablation, what's next is often just operator preference. Our study in Europace of 3,100+ patients: redo ablation cut death/stroke/HF by 35% vs. cardioversion (NNT=14). 🫀⚡
@nmarrouche @HanFengGHD @QMarashly
📄 doi.org/10.1093/europace/eua…
#AFib #EPeeps
Toby Markowitz retweeted
Look I think we all had money on what the first Cybercab accident would be but I don’t think any of us had “hit by 767”
Toby Markowitz retweeted
EVERY state needs this! And every hospital needs to follow their lead. 👇 👏👏👏
Important development in the national @ABMSCert MOC discussion: the Florida Board of Medicine has approved @nbpasadvocacy as a recognizing agency: "Once the final order is issued, physicians who hold qualifying NBPAS certification will be permitted to identify and advertise themselves as board certified in Florida."
flmedical.org/florida/Florid… @FloridaMedical
Why Has The Antiarrhythmic Drug Well Gone Dry? via @PeterKowey
sensible-med.com/p/why-has-t…
Toby Markowitz retweeted
I'm in search for someone to assist with milking cows on my dairy farm.
Must work well with udders.
Toby Markowitz retweeted
Transcatheter epicardial pacing of the human Bachmann’s bundle via the... sciencedirect.com/science/ar…
Toby Markowitz retweeted
A lot of us know it but repetition is good.
Also another reason to address factors leading to inappropriate shocks even with more lenient approach used these days
substack.com/home/post/p-204…
Toby Markowitz retweeted
Endurance exercise is heart-healthy usually. New study shows it can remodel pulmonary vein myocytes and create a pro-arrhythmic atrial substrate. The atrial fibrillation–athlete link, explained. Read more in #EHJ.
doi.org/10.1093/eurheartj/eh…
#AF #athlete #cardiotwitter @ESC_Journals @escardio
Toby Markowitz retweeted
Cardiac surgeon @georgetolisjr on @DRsLoungePod

































